Search research articles
Contact Us
Filters
Showing results (121-130 of 132) with videos related to
Page
of 14
Sort By:
The Journal of Biological Chemistry
|
February 18, 2016
Neutrophilic Cathepsin C Is Maturated by a Multistep Proteolytic Process and Secreted by Activated Cells during Inflammatory Lung Diseases
Yveline Hamon, Monika Legowska, Virginie Hervé, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 3, 2015
Development of a potent and selective cell penetrant Legumain inhibitor
Kerry A Ness, Sharon L Eddie, Catherine A Higgins, et al.
Pharmaceuticals (Basel, Switzerland)
|
April 27, 2024
Comprehensive Ocular and Systemic Safety Evaluation of Polysialic Acid-Decorated Immune Modulating Therapeutic Nanoparticles (PolySia-NPs) to Support Entry into First-in-Human Clinical Trials
Anitha Krishnan, David G Callanan, Victor G Sendra, et al.
British Journal of Cancer
|
September 11, 2020
Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer
Michelle K Greene, Ting Chen, Eifion Robinson, et al.
Journal of Cancer Policy
|
October 15, 2023
Health diplomacy in action: The cancer legacy of the Good Friday Agreement
Mark Lawler, Richard Sullivan, Ghassan K Abou-Alfa, et al.
Cell Death & Disease
|
October 30, 2020
RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer
Hajrah Khawaja, Andrew Campbell, Jamie Z Roberts, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
June 7, 2020
DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models
Michael C Johnston, Julie A Nicoll, Kelly M Redmond, et al.
Molecular Cancer Therapeutics
|
October 24, 2022
Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer
Hajrah Khawaja, Rebecca Briggs, Cheryl H Latimer, et al.
The European Respiratory Journal
|
January 19, 2019
Targeting of cathepsin S reduces cystic fibrosis-like lung disease
Donna M Small, Ryan R Brown, Declan F Doherty, et al.
Heliyon
|
February 2, 2024
Analysis of SARS-CoV-2 antibody seroprevalence in Northern Ireland during 2020-2021
Michelle K Greene, Peter Smyth, Andrew English, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 132) with videos related to
Sort By:
Page
of 14
The Journal of Biological Chemistry
|
February 18, 2016
Neutrophilic Cathepsin C Is Maturated by a Multistep Proteolytic Process and Secreted by Activated Cells during Inflammatory Lung Diseases
Yveline Hamon, Monika Legowska, Virginie Hervé, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 3, 2015
Development of a potent and selective cell penetrant Legumain inhibitor
Kerry A Ness, Sharon L Eddie, Catherine A Higgins, et al.
Pharmaceuticals (Basel, Switzerland)
|
April 27, 2024
Comprehensive Ocular and Systemic Safety Evaluation of Polysialic Acid-Decorated Immune Modulating Therapeutic Nanoparticles (PolySia-NPs) to Support Entry into First-in-Human Clinical Trials
Anitha Krishnan, David G Callanan, Victor G Sendra, et al.
British Journal of Cancer
|
September 11, 2020
Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer
Michelle K Greene, Ting Chen, Eifion Robinson, et al.
Journal of Cancer Policy
|
October 15, 2023
Health diplomacy in action: The cancer legacy of the Good Friday Agreement
Mark Lawler, Richard Sullivan, Ghassan K Abou-Alfa, et al.
Cell Death & Disease
|
October 30, 2020
RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer
Hajrah Khawaja, Andrew Campbell, Jamie Z Roberts, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
June 7, 2020
DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models
Michael C Johnston, Julie A Nicoll, Kelly M Redmond, et al.
Molecular Cancer Therapeutics
|
October 24, 2022
Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer
Hajrah Khawaja, Rebecca Briggs, Cheryl H Latimer, et al.
The European Respiratory Journal
|
January 19, 2019
Targeting of cathepsin S reduces cystic fibrosis-like lung disease
Donna M Small, Ryan R Brown, Declan F Doherty, et al.
Heliyon
|
February 2, 2024
Analysis of SARS-CoV-2 antibody seroprevalence in Northern Ireland during 2020-2021
Michelle K Greene, Peter Smyth, Andrew English, et al.
Page
of 14